We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Edwards Lifesciences (EW - Free Report) to post quarterly earnings of $0.60 per share in its upcoming report, which indicates a year-over-year decline of 9.1%. Revenues are expected to be $1.4 billion, down 12.2% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Edwards Lifesciences metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies' will reach $113.82 million. The estimate suggests a change of +56.1% year over year.
Analysts forecast 'Net Sales by Product Group- Surgical Structural Heart' to reach $254.51 million. The estimate points to a change of -4.4% from the year-ago quarter.
The consensus among analysts is that 'Net Sales by Product Group- Transcatheter Aortic Valve Replacement' will reach $1.03 billion. The estimate suggests a change of +2.2% year over year.
According to the collective judgment of analysts, 'Net Sales- Europe' should come in at $357.01 million. The estimate indicates a change of -2.9% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Outside of the United States' will reach $573.77 million. The estimate indicates a year-over-year change of -12.7%.
The average prediction of analysts places 'Net Sales- United States' at $849.03 million. The estimate points to a change of -9.8% from the year-ago quarter.
The combined assessment of analysts suggests that 'Net Sales- Japan' will likely reach $96.40 million. The estimate indicates a year-over-year change of -13%.
Analysts expect 'Net Sales- Rest of World' to come in at $120.36 million. The estimate points to a change of -32.7% from the year-ago quarter.
Edwards Lifesciences shares have witnessed a change of +0.8% in the past month, in contrast to the Zacks S&P 500 composite's -6.9% move. With a Zacks Rank #3 (Hold), EW is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts expect Edwards Lifesciences (EW - Free Report) to post quarterly earnings of $0.60 per share in its upcoming report, which indicates a year-over-year decline of 9.1%. Revenues are expected to be $1.4 billion, down 12.2% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Edwards Lifesciences metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies' will reach $113.82 million. The estimate suggests a change of +56.1% year over year.
Analysts forecast 'Net Sales by Product Group- Surgical Structural Heart' to reach $254.51 million. The estimate points to a change of -4.4% from the year-ago quarter.
The consensus among analysts is that 'Net Sales by Product Group- Transcatheter Aortic Valve Replacement' will reach $1.03 billion. The estimate suggests a change of +2.2% year over year.
According to the collective judgment of analysts, 'Net Sales- Europe' should come in at $357.01 million. The estimate indicates a change of -2.9% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Outside of the United States' will reach $573.77 million. The estimate indicates a year-over-year change of -12.7%.
The average prediction of analysts places 'Net Sales- United States' at $849.03 million. The estimate points to a change of -9.8% from the year-ago quarter.
The combined assessment of analysts suggests that 'Net Sales- Japan' will likely reach $96.40 million. The estimate indicates a year-over-year change of -13%.
Analysts expect 'Net Sales- Rest of World' to come in at $120.36 million. The estimate points to a change of -32.7% from the year-ago quarter.
View all Key Company Metrics for Edwards Lifesciences here>>>
Edwards Lifesciences shares have witnessed a change of +0.8% in the past month, in contrast to the Zacks S&P 500 composite's -6.9% move. With a Zacks Rank #3 (Hold), EW is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>